Auska: Subsidiary Delasatin Pudilan obtained drug registration certificate for injection use.

Aussein announcement states that its wholly-owned subsidiary, Jiangsu Aussein, recently received the Injection of Delafloxacin and Tobramycin Drug Registration Certificate approved by the drug supervision agency. This drug is the exclusive one approved for market in China, used for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, filling the gap in the domestic market. Delafloxacin has strong antibacterial activity, low resistance, and good safety. The sales of quinolone antibacterial drugs are estimated to be around 4.9 billion yuan in 2024, with great market potential. This approval will enrich the company's portfolio of anti-infection products, positively impacting its operations, but there is uncertainty surrounding product sales.